Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M20,645Revenue $M6,909Net Margin (%)12.4Z-Score2.2
Enterprise Value $M28,545EPS $1.6Operating Margin %16.6F-Score6
P/E(ttm))23.6Cash Flow Per Share $3.2Pre-tax Margin (%)12.0Higher ROA y-yY
Price/Book6.110-y EBITDA Growth Rate %12.7Quick Ratio0.9Cash flow > EarningsY
Price/Sales2.95-y EBITDA Growth Rate %7.1Current Ratio1.3Lower Leverage y-yY
Price/Cash Flow8.5y-y EBITDA Growth Rate %13.8ROA % (ttm)6.2Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)28.7Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M374ROI % (ttm)4.4Gross Margin Increase y-yY

Gurus Latest Trades with MYL

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MYLVanguard Health Care Fund 2014-09-30 Add1.24%$44.97 - $52.34
($48.56)
$ 53.5610%Add 223.41%15,444,880
MYLRay Dalio 2014-09-30 Buy 0.02%$44.97 - $52.34
($48.56)
$ 53.5610%New holding, 57106 sh.57,106
MYLMario Gabelli 2014-09-30 Reduce$44.97 - $52.34
($48.56)
$ 53.5610%Reduce -27.54%10,000
MYLJean-Marie Eveillard 2014-09-30 Reduce-0.06%$44.97 - $52.34
($48.56)
$ 53.5610%Reduce -34.81%809,603
MYLJean-Marie Eveillard 2014-06-30 Add0.07%$45.72 - $52.1
($49.11)
$ 53.569%Add 83.88%1,241,991
MYLScott Black 2014-06-30 Reduce-0.4%$45.72 - $52.1
($49.11)
$ 53.569%Reduce -26.46%201,925
MYLAndreas Halvorsen 2014-06-30 Sold Out -0.36%$45.72 - $52.1
($49.11)
$ 53.569%Sold Out0
MYLAndreas Halvorsen 2014-03-31 Buy 0.36%$42.26 - $57.2
($48.38)
$ 53.5611%New holding, 1776108 sh.1,776,108
MYLJean-Marie Eveillard 2014-03-31 Buy 0.09%$42.26 - $57.2
($48.38)
$ 53.5611%New holding, 675428 sh.675,428
MYLDavid Dreman 2014-03-31 Sold Out $42.26 - $57.2
($48.38)
$ 53.5611%Sold Out0
MYLJohn Hussman 2014-03-31 Reduce-0.47%$42.26 - $57.2
($48.13)
$ 53.5611%Reduce -75%50,000
MYLScott Black 2014-03-31 Reduce-0.16%$42.26 - $57.2
($48.13)
$ 53.5611%Reduce -10.63%274,571
MYLJoel Greenblatt 2014-03-31 Sold Out -0.01%$42.26 - $57.2
($48.38)
$ 53.5611%Sold Out0
MYLDavid Dreman 2013-12-31 Buy $37.865 - $44.5
($41.09)
$ 53.5630%New holding, 1221 sh.1,221
MYLJoel Greenblatt 2013-12-31 Reduce$37.865 - $44.5
($41.09)
$ 53.5630%Reduce -31.83%7,291
MYLJohn Hussman 2013-12-31 Reduce-0.53%$37.865 - $44.5
($41.09)
$ 53.5630%Reduce -55.95%200,000
MYLScott Black 2013-12-31 Reduce-0.23%$37.865 - $44.5
($41.09)
$ 53.5630%Reduce -14.62%307,214
MYLJohn Hussman 2013-09-30 Reduce-0.48%$30.37 - $38.95
($35.23)
$ 53.5652%Reduce -43.25%454,000
MYLJoel Greenblatt 2013-09-30 Reduce-0.16%$30.37 - $38.95
($35.23)
$ 53.5652%Reduce -91.73%10,695
MYLRay Dalio 2013-09-30 Sold Out -0.02%$30.37 - $38.95
($35.23)
$ 53.5652%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MYL is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
MYL Ray Dalio 2014-09-3057,1060.020.02New Buy
MYL Vanguard Health Care Fund 2014-09-3015,444,8804.131.8+223.41%
MYL John Paulson 2014-09-3012,494,7003.342.4+3%
MYL John Hussman 2014-09-3050,0000.010.19
MYL Scott Black 2014-09-30199,4060.051.3-1.25%
MYL Mario Gabelli 2014-09-3010,00000-27.54%
MYL Jean-Marie Eveillard 2014-09-30809,6030.220.09-34.81%
Premium Most recent portfolio changes are included for Premium Members only!


MYL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SHEEHAN JOHN DEVP and CFO 2014-11-26Sell19,475$57.5-4.07view
COURY ROBERT JExecutive Chairman 2014-11-25Sell165,700$55.78-1.11view
BRESCH HEATHER MCEO 2014-11-25Sell100,000$55.8-1.15view
Malik RajivPresident 2014-11-25Sell120,000$55.78-1.11view
HIGGINS MELINA EDirector 2014-11-07Buy14,000$52.455.17view
DIMICK NEIL FDirector 2014-09-18Sell5,432$48.2614.3view
DIMICK NEIL FDirector 2014-06-19Sell5,432$50.818.56view
Malik RajivPresident 2014-04-22Sell80,000$5010.32view
BRESCH HEATHER MCEO 2014-04-14Sell75,000$46.0719.73view
DIMICK NEIL FDirector 2014-03-20Sell5,813$53.083.92view

Press Releases about MYL :

    Quarterly/Annual Reports about MYL:

    News about MYL:

    Articles On GuruFocus.com
    Zoetis in a Growing Global Animal Health Industry Dec 03 2014 
    Weekly CFO Sells Highlight: Hospira Inc, Rockwood Holdings Inc, Mylan Inc. Nov 30 2014 
    Scott Black’s Top First Quarter Holdings Apr 23 2014 
    Should You Buy Actavis? Mar 18 2014 
    Scott Black’s Top Five Stocks at Year End Jan 09 2014 
    Scott Black’s Top Five Third Quarter Holdings Oct 22 2013 
    S&P Winners Broadly Held by Billionaires Oct 06 2013 
    Weekly CEO Sells Highlight: Workday Inc., Kirby Corp., Mylan Inc., Infinera Corporation Sep 09 2013 
    Three Stocks for a Recovering Europe Jul 29 2013 
    comment on MYL Jan 03 2013 

    More From Our Partners
    Actavis to Appeal Ruling Regarding Namenda IR Sales - Analyst Blog Dec 16 2014 - ZACKS

    More From Other Websites
    Mylan to Present at the J.P. Morgan 33rd Annual Healthcare Conference Dec 17 2014
    Mylan to Present at the J.P. Morgan 33rd Annual Healthcare Conference Dec 17 2014
    Teva Upgraded On Strength Of Copaxone MS Drug Dec 12 2014
    MiMedx Group, Conn's, Mylan, Pfizer and Amgen highlighted as Zacks Bull and Bear of the Day Dec 12 2014
    Mylan Among First to Launch Generic Celebrex Dec 11 2014
    Teva Pharm sees 2015 revenue lower than forecast Dec 11 2014
    Mylan Launches Generic Robaxin® Injection Dec 11 2014
    Mylan Launches First Generic Version of Orapred ODT® Dec 11 2014
    Mylan Launches Generic Robaxin® Injection Dec 11 2014
    Mylan Launches First Generic Version of Orapred ODT® Dec 11 2014
    Mylan pays bonuses to ease 'spinversion' Dec 10 2014
    Mylan Launches One of First Available Generic Versions of Celebrex® Capsules Dec 10 2014
    Merck-Cubist Deal Is On Despite Patent Setback Dec 09 2014
    Two Gauges That Point To Fund Buying In A Stock Dec 08 2014
    World TeamTennis and Mylan Announce Title Sponsorship Extension Through 2017 Dec 08 2014
    World TeamTennis and Mylan Announce Title Sponsorship Extension Through 2017 Dec 08 2014
    Medical Issues Keep Climbing Into Sell Zone Dec 04 2014
    GlaxoSmithKline scraps £7bn sale of old drugs Dec 04 2014
    Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through... Dec 04 2014
    Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through... Dec 04 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK